Responding to questionnaires after taking either the drug or a dummy pill, 73 percent of the women on bremelanotide reported feeling genitally aroused, compared with 23 percent given the placebo; and 43 percent of the bremelanotide group said the treatment augmented their sexual desire, against only 19 percent of those on dummy pills.
Women in the treatment group also were slightly more likely to have sex with their partners during the course of the trial than were those in the control group, although who initiated the romps was not specified.
Larger trials of the drug at some 20 clinical centers around the US are now under way. Among other things, the researchers will try adjusting the dosage to see if more bremelanotide may provoke a more robust response with a minimum of unpleasant or embarrassing side effects.
For example, researchers are as yet unsure whether sustained use of bremelanotide will end up doing what the drug was meant to do in the first place, and bestow on its beaming clients a truly healthy tan.
RSS